Your snapshot
Amass's score and Biomedical & Pharma Research Intelligence position
Life sciences intelligence, unified — publications, trials, drugs, genes, regulatory approvals, and patents in one cross-linked connector
Description
**The biomedical intelligence layer for AI** Search and reason across 60M+ cross-linked life science records — including peer-reviewed publications, clinical trials, drugs, genes, regulatory approvals, and patents — from a single connector. Instead of searching individual databases, Amass gives Claude access to a unified biomedical knowledge layer where entities are linked across sources, enabling richer retrieval, evidence synthesis, and scientific reasoning with full source attribution. ## What you can do Use Amass to power workflows such as: - Scientific literature reviews - Drug and target discovery - Clinical trial landscape analysis - Regulatory intelligence (FDA & EMA) - Drug approval and label comparison - Patent landscape and freedom-to-operate research - Gene, target and biomarker exploration - Due diligence and competitive intelligence - AI agents that require grounded biomedical evidence ## Included *Cores **BioMedCore** 40M+ peer-reviewed publications from PubMed and PubMed Central, including 3.6M+ with full text and 29M+ with abstracts. **TrialCore** 1.2M+ clinical trials from ClinicalTrials.gov and international registries (ChiCTR, CTRI, EU-CTR, JPRN, IRCT, and more), linked to drugs, diseases, publications and regulatory outcomes. **DrugCore** 22K+ harmonized drugs and molecules — including 5,200+ approved — with modality, mechanism of action, targets, development stage, synonyms, structures and ChEMBL relationships. **RegulatoryCore** 7K+ FDA and EMA approvals, backed by 466K+ parsed document sections — labels, SmPCs, EPARs, review documents and regulatory history. **GeneCore** 42K+ human genes enriched with target intelligence, druggability, clinical evidence, tractability, DepMap essentiality, safety liabilities and cross-links to drugs, trials and publications. **PatentCore** *(Preview)* 16M+ life science patents with full-text search, CPC/IPC classifications, patent families, assignees, inventors and chemical compounds.
The Primary Subcategory used for this profile’s headline score.
Other Subcategories where the Integration is listed.
Get updates when Amass Connector’s Discoverability Score or category rank changes.
Claude Discoverability Score
Live · refreshed daily. Last refreshed#3of 19competitors
Shown to buyers in 91.7% of contested Runs.
One core score. Three important factors to discoverability.
Amass organic discovery report
See how Amass appears in Biomedical & Pharma Research Intelligence, where it ranks, and how it compares with the wider Claude Connector ecosystem.
Your snapshot
Amass's score and Biomedical & Pharma Research Intelligence position
Industry report
State of Agent Discovery
30-day industry report
The levers are the listing surface agents actually read: names, descriptions, keywords, tool metadata, and registry health. Which lever matters depends on where discovery breaks, which is what continuous measurement shows.
As of 2026-09-28, Amass Connector competes with AdisInsight, Clinical Trials, Maven Bio, Boltz API, Cortellis CMC Intelligence, EDEN by Basecamp Research, ICD-10 Codes, Inductive Bio, Open Targets, Synthesize Bio, Convoke, Cortellis Competitive Intelligence, DocCheck Flexikon, DocNexus Advanced Search MCP, mcp.gosset.ai, OFF-X Safety Assistant, PubCrawl, Rhizome AI in Claude Biomedical & Pharma Research Intelligence, ranked by public Discoverability Score.
As of 2026-09-28, Amass Connector ranks #3 of 19 in Claude Biomedical & Pharma Research Intelligence with a Discoverability Score of 92/100 (Winning).
This profile uses the geography attached to the latest public registry snapshot: US. Locale tags are intentionally omitted.